HSP60 in cancer: a promising biomarker for diagnosis and a potentially useful target for treatment

J Drug Target. 2022 Jan;30(1):31-45. doi: 10.1080/1061186X.2021.1920025. Epub 2021 May 3.

Abstract

Heat shock proteins (HSPs), most of which are molecular chaperones, are highly conserved proteins produced by cells under physiological stress or pathological conditions. HSP60 (57-69 kDa) can promote or inhibit cell apoptosis through different mechanisms, and its abnormal expression is also related to tumour cell metastasis and drug resistance. In recent years, HSP60 has received increasing attention in the field of cancer research due to its potential as a diagnostic and prognostic biomarker or therapeutic target. However, in different types of cancer, the specific mechanisms of abnormally expressed HSP60 in tumour carcinogenesis and drug resistance are complicated and still require further study. In this article, we comprehensively review the regulative mechanisms of HSP60 on apoptosis, its applications as a cancer diagnostic biomarker and a therapeutic target, evidence of involvement in tumour resistance and the applications of exosomal HSP60 in liquid biopsy. By evaluating the current findings of HSP60 in cancer research, we highlight some core issues that need to be addressed for the use of HSP60 as a diagnostic or prognostic biomarker and therapeutic target in certain types of cancer.

Keywords: HSP60; cancer diagnostic biomarker; exosomal HSP60; therapeutic target; tumour resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis
  • Biomarkers, Tumor / metabolism
  • Chaperonin 60 / metabolism
  • Chaperonin 60 / therapeutic use
  • Heat-Shock Proteins / metabolism
  • Heat-Shock Proteins / therapeutic use
  • Humans
  • Mitochondrial Proteins
  • Neoplasms* / diagnosis
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism

Substances

  • Biomarkers, Tumor
  • Chaperonin 60
  • HSPD1 protein, human
  • Heat-Shock Proteins
  • Mitochondrial Proteins